Enikia is an innovative dietary supplement that emerged after years of research and development starting in 2015 and ending in 2021.
Enikia's formula combines cutting-edge science with natural ingredients to offer a comprehensive solution in the field of modern medicine.
Dr. Horacio Astudillo witnessed how this supplement transformed the quality of life of those who used it, validating its effectiveness and relevance in health care. Enikia represents not only a product, but a promise of hope and vitality for a healthier and fuller life.
TIMELINE
2015
PEI (INNOVATION STIMULUS PROGRAM) -CONACYT
Project ID: 222470
Development and validation of a new supplement and antiglycant for metabolic syndrome. Part I
2015
PEI (INNOVATION STIMULUS PROGRAM) -CONACYT
Project ID: 222470
Development and validation of a new supplement and antiglycant for metabolic syndrome. Part I
2016
PEI (INNOVATION STIMULUS PROGRAM) -CONACYT
Project ID: 231815
Development and validation of a new nutraceutical for the treatment of metabolic syndrome. Part II
2016
PEI (INNOVATION STIMULUS PROGRAM) -CONACYT
Project ID: 231815
Development and validation of a new nutraceutical for the treatment of metabolic syndrome. Part II
2017
PEI (INNOVATION STIMULUS PROGRAM) -CONACYT
Project ID: 242306
Development and validation of a new nutraceutical for the treatment of metabolic syndrome. Part III
2017
PEI (INNOVATION STIMULUS PROGRAM) -CONACYT
Project ID: 242306
Development and validation of a new nutraceutical for the treatment of metabolic syndrome. Part III
2018 – 2021
INTELLECTUAL PROPERTY
During these years, the focus was on rigorous research and innovative development, granting us patents in 24 countries.
Estados Unidos – México – OAPI – Rusia – Panamá – China – Hong Kong
2018 – 2021
INTELLECTUAL PROPERTY
During these years, the focus was on rigorous research and innovative development, granting us patents in 24 countries.
Estados Unidos – México – OAPI – Rusia – Panamá – China – Hong Kong
2022 – 2023
ENIKIA® GOES ON THE MARKET
It is officially launched as a dietary supplement that combines amino acids and antioxidants, with nanotechnology to prevent and reverse cellular damage caused by chronic-degenerative diseases.
2022 – 2023
ENIKIA® GOES ON THE MARKET
It is officially launched as a dietary supplement that combines amino acids and antioxidants, with nanotechnology to prevent and reverse cellular damage caused by chronic-degenerative diseases.
2023 – 2024
INTELLECTUAL PROPERTY
As a result of the research, 21 more patents have been granted, giving a total pf 44 patents granted.
India – EPO
2023 – 2024
INTELLECTUAL PROPERTY
As a result of the research, 21 more patents have been granted, giving a total pf 44 patents granted.
India – EPO
Patentes –
• United States -Combination of bioenergetic and nutra-epigenetic metabolic regulators, nutraceutical compounds in conventional and nanotechnological combinations to reverse and prevent cellular senescence accelerated by chronic damage produced by diabetes and other complex chronic-degenerative diseases. US 10 285 963 B2)
• México -Combination of bioenergetic and nutra-epigenetic metabolic regulators, nutraceutical compounds in conventional and nanotechnological combinations to reverse and prevent cellular senescence accelerated by chronic damage produced by diabetes and other complex chronic-degenerative diseases. MX/a/2017/007448)
• OAPI (17 countries) -Combination of metabolic regulators and nutraceuticals for the prevention of chronic damage from diabetes. WO2017213486A2)
• Russia Use of a composition consisting of the amino acids glycine, arginine, cysteine and resveratrol to reduce the severity of diabetes and high body fat, cholesterol, uric acid, blood glucose and accelerated aging in animals and humans. RU2749950C2)
• Panamá Combination of bioenergetic and nutra-epigenetic metabolic regulators, nutraceutical compounds in conventional and nanotechnological combinations to reverse and prevent cellular senescence accelerated by chronic damage produced by diabetes and other complex chronic-degenerative diseases. (Patente 92465-01)
• China Combination of metabolic regulators and compounds to prevent and reduce the severity of chronic damage caused by diabetes. CN 109890369 B)
• Hong Kong Combination of metabolic regulators and compounds to prevent and reduce the severity of chronic damage caused by diabetes (Patente HK40010029)
- India Combination of metabolic regulators and nutraceuticals for the prevention of chronic damage from diabetes. (Patente 461531)
- EPO – Composition comprising resveratrol, glycine, arginine and cysteine for use in treating metabolic syndrome. (Patente EP3470060B1)
